Fundraising Fox
NKILT Therapeutics
Founded 2021 · 9 employees on LinkedIn · 1 known investors
Find your way into NKILT Therapeutics
Sign up to see every warm intro you have to NKILT Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NKILT Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NKILT Therapeutics is a cell therapy biotech developing engineered immune cells, starting with natural killer (NK) cells, to target leukemias and solid tumors. It uses a proprietary Chimeric ILT-Receptor (CIR) binding technology to create off-the-shelf, allogeneic cancer treatments targeting the HLA-G immune checkpoint molecule.
Founders & leadership
NKILT Therapeutics was founded in 2021 by Henri Bayle.
HB
Henri BayleFounder · Chief Scientific Officer and Chief Development OfficerHenri Bayle is a biotechnology scientist and executive with extensive background in immunology, molecular biology, and cell signaling who has led discovery programs in translational studies. He is co-founder of NKILT Therapeutics, developing engineered cell immunotherapies for cancer treatment.
Investors · 1
Related companies · 4
NKore BiotherapeuticsNKore BioTherapeutics is a cellular-based biotherapeutics company developing an allogeneic immunotherapy platform based on a proprietary method of activating natural killer (NK) cells, called Supercharged NK (sNK) cells. Its lead therapy, NK101, targets solid and blood cancers in adult and pediatric patients, with human clinical trials planned in the United States beginning in 2027.
CelularityCelularity is a regenerative and cellular medicine company developing and commercializing biomaterial products and allogeneic, cryopreserved cell therapies derived from the postpartum placenta to target age-related diseases. It operates its own integrated manufacturing, translational research, and biobanking facility for placenta-derived cellular medicines and advanced biomaterials.
Nok TherapeuticsNOK Therapeutics is a biotech company developing autologous Natural Killer (NK) cell therapies for cancer treatment that avoid the need for lymphodepletion. The company is an early-stage oncology/immunotherapy business raising capital through a Regulation A+ pre-IPO offering.
Nkarta, Inc.Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments. Its lead program, NKX019, targets the CD19 antigen for B cell-mediated autoimmune conditions such as lupus nephritis and systemic sclerosis.
Companies working in the same space as NKILT Therapeutics.
In the news
Frequently asked questions
- What does NKILT Therapeutics do?
- NKILT Therapeutics is a cell therapy biotech developing engineered immune cells, starting with natural killer (NK) cells, to target leukemias and solid tumors. It uses a proprietary Chimeric ILT-Receptor (CIR) binding technology to create off-the-shelf, allogeneic cancer treatments targeting the HLA-G immune checkpoint molecule.
- Who founded NKILT Therapeutics?
- NKILT Therapeutics was founded by Henri Bayle in 2021.
- Who are NKILT Therapeutics's investors?
- NKILT Therapeutics's investors include The Innovation Space.